Quantcast

Latest Erlotinib Stories

2011-02-28 13:29:37

European Multidisciplinary Conference in Thoracic Oncology news The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show. Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this finding from the international TITAN study at the European Multidisciplinary...

2011-02-25 13:16:36

European Multidisciplinary Conference in Thoracic Oncology news Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib. Dr Rafael Rosell and colleagues reported their findings at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011 in Lugano, Switzerland. The researchers studied 55 patients with non-small cell lung cancer, whose tumors had...

2011-02-22 07:37:00

SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the execution of a definitive agreement relating to the collaborative research, development and commercialization of Proacta's PR509, a hypoxia-activated pro-drug for the treatment of cancer. (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-a ) (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b ) "We have worked diligently to arrive at this...

2011-01-04 07:30:00

WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Biotech Showcase 2011 on Tuesday, January 11, 2011 at 10:00 a.m. PT at the Parc 55 Wyndham hotel in San Francisco. Dr. Horobin's presentation will include the recently reported results from a randomized phase 2 study, which showed a four-month survival advantage when...

2010-12-15 14:59:52

University of Colorado-developed treatment effective in Phase 2 Trials in a biomarker-selected group of patients A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results presented today from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals. The phase 2 results show that the combination of entinostat (Syndax's...

2010-12-15 07:31:00

(IVANHOE NEWSWIRE)-- Combining epigenetic therapy and molecular targeted therapy has shown promising results for combating advanced lung cancer. Epigenetic therapy is designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, evaluates whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib, a drug used to treat patients...

2010-12-10 17:30:00

WALTHAM, Mass., Dec. 10, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas. The following poster discussions...

2010-12-09 17:20:06

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago. Epigenetics...

2010-12-09 07:45:00

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation.(1) The updated LUX-Lung 1 data will be presented at...

2010-12-09 07:45:00

WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.